Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | GRAMD1A | Q96CP6 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.36 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291670 | 0.95 | ALK (0.38) | CRBNDDB1GPR119ARALK | |
| SCHEMBL22291558 | 0.87 | CRBN (0.49) | CRBNDDB1AR | |
| SCHEMBL22291550 | 0.84 | DDB1 (0.44) | CRBNDDB1GPR119ALKGRAMD1A | |
| SCHEMBL29369780 | 0.84 | DDB1 (0.44) | CRBNDDB1GPR119ALKGRAMD1A | |
| SCHEMBL29367335 | 0.79 | CRBN (0.44) | CRBNDDB1GPR119ALKHRH3 | |
| SCHEMBL22291497 | 0.79 | CRBN (0.44) | CRBNDDB1GPR119ALKHRH3 | |
| SCHEMBL29614689 | 0.79 | CRBN (0.51) | CRBNDDB1ARALK | |
| SCHEMBL29257436 | 0.79 | CRBN (0.51) | CRBNDDB1ARALK | |
| SCHEMBL22291386 | 0.79 | CRBN (0.51) | CRBNDDB1ALK | |
| SCHEMBL29617074 | 0.79 | CRBN (0.51) | CRBNDDB1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-03-16 | — | — | US | disclosed |
| EP-3917526-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 56/4885DDB1 699/4885GPR119 3031/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 56/4885DDB1 699/4885GPR119 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.